Intravascular devices and fibrosis-inducing agents

• US 20050149173A1
• Filed: 11/10/2004
• Published: 07/07/2005
• Est. Priority Date: 11/10/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Toleikis, Philip M., Gravett, David M., Liggins, Richard T., Maiti, Arpita, Guan, Dechi, Signore, Pierre E.
• Application Number:
  US10/986,450
• Publication Number:
  US 20050149173A1
• Time in Patent Office: Days
• US Class Current: 623/1.420
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61B 17/11 for performing anastomosis; Buttons for anastomosis
• CPC Class Codes: A61B 17/12022 Occluding by internal devices, e.g. balloons or releasable wires plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20
• CPC Class Codes: A61B 17/12045 double occlusion, e.g. during anastomosis
• CPC Class Codes: A61B 17/12136 Balloons
• CPC Class Codes: A61B 17/1215 comprising additional materials, e.g. thrombogenic, having filaments, having fibers, being coated
• CPC Class Codes: A61B 17/12172 having a pre-set deployed three-dimensional shape methods of manufacturing A61B2017/00526
• CPC Class Codes: A61B 17/12177 comprising additional materials, e.g. thrombogenic, having filaments, having fibers or being coated
• CPC Class Codes: A61B 17/12186 liquid materials adapted to be injected
• CPC Class Codes: A61B 17/1219 expandable in contact with liquids
• CPC Class Codes: A61B 2017/00004 (bio)absorbable, (bio)resorbable, resorptive for implantable prostheses A61F2210/0004
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.

Claims

1. A method of inducing fibrosis in a patient, comprising delivering locally to a tissue proximate to a blood vessel lumen in a patient in need thereof, wherein the blood vessel has a luminal surface, a fibrosing agent or a composition comprising a fibrosing agent, wherein the agent induces fibrosis.

2. The method of claim 1 wherein the tissue is diseased tissue.

3. The method of claim 1 wherein the tissue is a blood vessel wall in the vicinity of a diseased tissue.

4. The method of claim 1 wherein the fibrosing agent or the composition comprising the fibrosing agent is delivered to a luminal surface of the blood vessel.

5. The method of claim 1 wherein the fibrosing agent or a composition comprising the fibrosing agent is delivered into the tissue.

10. The method of claim 1, further comprising deploying an intravascular device within the blood vessel, wherein the device comprises the fibrosing agent or the composition comprising the fibrosing agent, wherein the device is configured to locally deliver the fibrosing agent or composition comprising the fibrosing agent to a tissue in the vicinity of the device once it is deployed, where the fibrosing agent induces fibrosis.

111. The method of claim 1 wherein the fibrosing agent promotes regeneration.

112. The method of claim 1 wherein the fibrosing agent promotes angiogenesis.

113. The method of claim 1 wherein the fibrosing agent promotes fibroblast migration.

114. The method of claim 1 wherein the fibrosing agent promotes fibroblast proliferation.

115. The method of claim 1 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).

116. The method of claim 1 wherein the fibrosing agent promotes tissue remodeling.

117. The method of claim 1 wherein the fibrosing agent promotes adhesion between the device and a host into which the device is implanted.

118. The method of claim 1 wherein the fibrosing agent is or comprises an arterial vessel wall irritant.

119. The method of claim 1 wherein the fibrosing agent is or comprises an arterial vessel wall irritant selected from the group consisting of talcum powder, metallic beryllium and oxides thereof, copper, silica, crystalline silicates, talc, quartz dust, and ethanol.

120. The method of claim 1 wherein the fibrosing agent is or comprises silk.

121. The method of claim 1 wherein the fibrosing agent is or comprises silkworm silk.

122. The method of claim 1 wherein the fibrosing agent is or comprises spider silk.

123. The method of claim 1 wherein the fibrosing agent is or comprises recombinant silk.

124. The method of claim 1 wherein the fibrosing agent is or comprises raw silk.

125. The method of claim 1 wherein the fibrosing agent is or comprises hydrolyzed silk.

126. The method of claim 1 wherein the fibrosing agent is or comprises acid-treated silk.

127. The method of claim 1 wherein the fibrosing agent is or comprises acylated silk.

128. The method of claim 1 wherein the fibrosing agent is or comprises mineral particles.

129. The method of claim 1 wherein the fibrosing agent is or comprises chitosan.

130. The method of claim 1 wherein the fibrosing agent is or comprises polylysine.

131. The method of claim 1 wherein the agent is or comprises a component of extracellular matrix.

132. The method of claim 1 wherein the agent is or comprises a component of extracellular matrix, wherein the component is selected from collagen, fibrin, and fibrinogen.

133. The method of claim 1 wherein the fibrosing agent is or comprises fibronectin.

134. The method of claim 1 wherein the fibrosing agent is or comprises bleomycin or an analogue or derivative thereof.

135. The method of claim 1 wherein the fibrosing agent is or comprises CTGF.

136. The method of claim 1 wherein the agent is or comprises a peptide containing an RGD sequence.

137. The method of claim 1 wherein the agent is or comprises poly(ethylene-co-vinylacetate).

138. The method of claim 1 wherein the agent is or comprises an adhesive.

139. The method of claim 1 wherein the adhesive is or comprises a cyanoacrylate.

140. The method of claim 1 wherein the agent is or comprises a crosslinked poly(ethylene glycol)—

methylated collagen.

141. The method of claim 1 wherein the agent is or comprises an inflammatory cytokine.

142. The method of claim 1 wherein the agent is or comprises a growth factor.

143. The method of claim 1 wherein the agent is or comprises a member selected from the group consisting of TGFβ

, PDGF, VEGF, bFGF, TNFα

, NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone.

146. The method of claim 1, further comprising delivering to the patient an inflammatory cytokine.

147. The method of claim 1, further comprising delivering to the patient an agent that stimulates cell proliferation.

150. The method of claim 1, further comprising an agent that inhibits infection.

6-9. -9. (canceled)

11-110. -110. (canceled)

144. (canceled)

145. (canceled)

148. (canceled)

149. (canceled)

151-1738. -1738. (canceled)